Log In
Print this Print this

basiliximab (Simulect)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionChimeric mAb against iInterleukin-2 (IL-2) receptor alpha chain (CD25) receptor on activated T cells
Molecular Target Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of ActionBinds interleukin-2 (IL-2) receptor alpha chain (CD25); Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today